
PROTHENA CORP PUBLIC LTD CO — Investor Relations & Filings
Prothena Corporation is a late-stage clinical biotechnology company specializing in the science of protein dysregulation. The company leverages its expertise in the biology of misfolded proteins to discover and develop novel therapeutics. Its primary focus is on advancing a diverse pipeline of investigational treatments for neurodegenerative conditions and rare peripheral amyloid diseases. Prothena's scientific approach integrates insights into neurological dysfunction and the mechanisms of protein misfolding to create antibody-based therapies designed to provide clinically meaningful benefits for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-15 | English | |
| DEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-03-27 | English | |
| 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | |
| 10-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | |
| 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-19 | English | |
| 8-K | 2025-12-12 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 46362587 | 8-K | 2026-05-15 | English | ||
| 33065546 | DEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-03-27 | English | ||
| 32893883 | 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | ||
| 32893885 | 10-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | ||
| 32893884 | 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-19 | English | ||
|
2025
10 filings
| |||||
| 12590207 | 8-K | 2025-12-12 | English | ||
| 12590208 | 8-K | 2025-11-19 | English | ||
| 12590209 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 12590210 | Major Shareholding Notification 2025 | 2025-11-12 | English | ||
| 12590211 | Major Shareholding Notification 2025 | 2025-11-12 | English | ||
| 12590212 | 10-Q | 2025-11-06 | English | ||
| 12590213 | DEFA14A | 2025-11-06 | English | ||
| 12590214 | 8-K | 2025-11-06 | English | ||
| 12590215 | Major Shareholding Notification 2025 | 2025-10-17 | English | ||
| 12590216 | DEFA14A | 2025-10-07 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Repare Therapeutics Inc.
A clinical-stage oncology company developing targeted cance…
|
RPTX | US | Professional, scientific and te… |
|
Replimune Group, Inc.
A clinical-stage biotech developing oncolytic immunotherapi…
|
REPL | US | Professional, scientific and te… |
|
ReproCELL Incorporated
Provider of stem cell technology and services for research …
|
4978 | JP | Professional, scientific and te… |
|
RESEARCH FRONTIERS INC
Develops and licenses patented light-control technology for…
|
REFR | US | Professional, scientific and te… |
|
RESONANCE HEALTH LIMITED
Develops non-invasive MRI software for quantitative analysi…
|
RHT | AU | Professional, scientific and te… |
|
Respiratorius AB
A research company developing innovative drug candidates, p…
|
RESP | SE | Professional, scientific and te… |
|
REVELATION BIOSCIENCES, INC.
Clinical-stage biopharma developing immunologic therapies t…
|
REVB | US | Professional, scientific and te… |
|
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Clinical-stage biopharma developing therapeutics for CNS, r…
|
RVPH | US | Professional, scientific and te… |
|
Revolution Medicines, Inc.
Clinical-stage precision oncology company developing therap…
|
RVMD | US | Professional, scientific and te… |
|
R&G PharmaStudies Co., Ltd.
Full-service CRO providing clinical research solutions for …
|
301333 | CN | Professional, scientific and te… |
PROTHENA CORP PUBLIC LTD CO via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32782/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32782 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32782 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32782 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32782}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PROTHENA CORP PUBLIC LTD CO (id: 32782)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.